NEW YORK (TheStreet) -- Jefferies increased its price target on Cubist Pharmaceuticals (CBST) to $88 and set a "buy" rating. New antibiotic launches that will expand profit margin drove the firm's decision.
The stock was up 1.73% to $73.49 in pre-market trading on Monday.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts